To read the full story, subscribe or sign in.

Zai Lab nabs $761M via secondary listing in Hong Kong

Sep. 28, 2020

HONG KONG – U.S. listed Chinese biotech company Zai Lab Ltd. has raised $761 million in its secondary listing on the Hong Kong Stock Exchange.

BioWorld Financings Cancer IPO Asia-Pacific

FDA says changes in Dexcom G6, G7 sensors constitute misbranding

BioWorld MedTech

The U.S. FDA’s March 4, 2025, warning letter to Dexcom Inc. is a well-detailed but heavily redacted document explaining the agency’s misgivings about procedures...

Today's news in brief

BioWorld

BioWorld briefs for March 28, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 28, 2025

CMV history cited in DMD liver death on Sarepta’s Elevidys

BioWorld

Wall Street was weighing the gravity of the death from acute liver failure of a patient who was treated for Duchenne muscular dystrophy (DMD) with Sarepta...

UK government abolishes NHS England

BioWorld MedTech

In a move that surprised many across the health care sector, the U.K. government decided to scrap NHS England, the body which runs the national health service...